Growth Metrics

Fulgent Genetics (FLGT) Net Income towards Common Stockholders (2016 - 2025)

Fulgent Genetics' Net Income towards Common Stockholders history spans 11 years, with the latest figure at -$23.4 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 297.72% year-over-year to -$23.4 million; the TTM value through Dec 2025 reached -$60.5 million, down 41.69%, while the annual FY2025 figure was -$60.5 million, 41.69% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$23.4 million at Fulgent Genetics, down from -$6.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $200.7 million in Q1 2021 and bottomed at -$213.5 million in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$10.0 million (2023), against an average of $9.2 million.
  • The largest annual shift saw Net Income towards Common Stockholders skyrocketed 11856.94% in 2021 before it crashed 1075.95% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $103.7 million in 2021, then tumbled by 305.91% to -$213.5 million in 2022, then skyrocketed by 39.97% to -$128.1 million in 2023, then soared by 95.41% to -$5.9 million in 2024, then plummeted by 297.72% to -$23.4 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Net Income towards Common Stockholders are -$23.4 million (Q4 2025), -$6.6 million (Q3 2025), and -$19.0 million (Q2 2025).